Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease
- PMID: 32529662
- DOI: 10.1002/mds.28187
Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease
Comment in
-
Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy".Mov Disord. 2020 Nov;35(11):2120-2121. doi: 10.1002/mds.28329. Mov Disord. 2020. PMID: 33463751 No abstract available.
-
Toward a Personalized Approach to Parkinson's Cell Therapy.Mov Disord. 2020 Nov;35(11):2119-2120. doi: 10.1002/mds.28328. Mov Disord. 2020. PMID: 33463754 No abstract available.
Comment on
-
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease.N Engl J Med. 2020 May 14;382(20):1926-1932. doi: 10.1056/NEJMoa1915872. N Engl J Med. 2020. PMID: 32402162 Free PMC article.
References
-
- Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment [published online ahead of print, 2020 June 23]. J Neurol Neurosurg Psychiatry 2020. doi: 10.1136/jnnp-2019-322338
-
- Parmar M, Grealish S, Henchcliffe C. The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci 2020;21(2):103-115.
-
- Song B, Cha Y, Ko S, et al. Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. J Clin Invest 2020;130(2):904-920.
-
- Schweitzer J, Song B, Herrington T, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease. N Engl J Med 2020;382(20):1926-1932.
-
- Roussakis AA, Politis M, Towey D, Piccini P. Serotonin-to-dopamine transporter ratios in Parkinson disease: relevance for dyskinesias. Neurology 2016;86(12):1152-1158.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical